Titlebook: Chronic Kidney Disease and Hypertension; Matthew R. Weir,Edgar V. Lerma Book 2015 Springer Science+Business Media New York 2015 BP Monitor

赞美

书目名称Chronic Kidney Disease and Hypertension影响因子(影响力)




书目名称Chronic Kidney Disease and Hypertension影响因子(影响力)学科排名




书目名称Chronic Kidney Disease and Hypertension网络公开度




书目名称Chronic Kidney Disease and Hypertension网络公开度学科排名




书目名称Chronic Kidney Disease and Hypertension被引频次




书目名称Chronic Kidney Disease and Hypertension被引频次学科排名




书目名称Chronic Kidney Disease and Hypertension年度引用




书目名称Chronic Kidney Disease and Hypertension年度引用学科排名




书目名称Chronic Kidney Disease and Hypertension读者反馈




书目名称Chronic Kidney Disease and Hypertension读者反馈学科排名

affluent

978-1-4939-4704-1Springer Science+Business Media New York 2015

cyanosis

eucalyptus

Clinical Hypertension and Vascular Diseaseshttp://image.papertrans.cn/c/image/226386.jpg

Eviction

轻信

轻信

https://doi.org/10.1007/978-3-319-21103-9e is steadily escalating to hazardous proportions due to the increasing incidence of hypertension, diabetes, metabolic syndrome, and other risk factors. Hypertension can be a cause or consequence of CKD. Nevertheless, the coexistence of hypertension and CKD portends poor prognosis due to the occurre

Excitotoxin

Story Credibility in Narrative Argumentsute to hypertension in these patients, including volume expansion and activation of the renin–angiotensin–aldosterone system. This chapter deals with the role of the sympathetic nervous system in hypertension and CKD progression in these patients and with the mechanisms that can contribute to the ac

nitroglycerin

https://doi.org/10.1007/978-1-349-06892-0 models and new options to block the renin–angiotensin–aldosterone axis such as renin inhibitors, angiotensin II type 2 receptor agonists, angiotensin vaccines and aldosterone synthase inhibitors are under scrutiny with variable results so far. Interventions in different hormones and autacoids, enzy

凝乳

Key Currencies and Financial Centresor blocker (ARB) or a direct renin inhibitor (DRI) similarly reduces blood pressure (BP) when each is used as monotherapy in patients with hypertension. Both ACE inhibitors and ARBs also slow down the progressive decline in renal function, which marks renal injury, particularly in patients with diab